Recent Developments in the Third Generation Inhibitors of Bcr-Abl for Overriding T315I Mutation

By  

Current Medicinal Chemistry, Vol. 18, Iss. 14, 2011-05 ,pp. : 2146-2157

Bentham Science Publishers

Access to resources Recommend Favorite

New SRC/ABL inhibitors for chronic myeloid leukemia therapy show selectivity for T315I ABL mutant CD34⁺ cells

By Santucci Maria   Mancini Manuela   Corradi Valentina   lacobucci Ilaria   Martinelli Giovanni   Botta Maurizio   Schenone Silvia  

Investigational New Drugs, Vol. 28, Iss. 6, 2010-12 ,pp. : 876-878

Springer Publishing Company

Access to resources Recommend Favorite

New Opportunities to Treat the T315I-Bcr-Abl Mutant in Chronic Myeloid Leukaemia: Tyrosine Kinase Inhibitors and Molecules that Act by Alternative Mechanisms

By  

Current Medicinal Chemistry, Vol. 17, Iss. 13, 2010-05 ,pp. : 1220-1245

Bentham Science Publishers

Access to resources Recommend Favorite

Dual Inhibitors of Src and Abl Tyrosine Kinases

By  

Drug Design Reviews - Online, Vol. 1, Iss. 3, 2004-07 ,pp. : 203-214

Bentham Science Publishers

Access to resources Recommend Favorite

Effects of BCR-ABL Inhibitors on Anti-Tumor Immunity

By  

Current Medicinal Chemistry, Vol. 18, Iss. 34, 2011-12 ,pp. : 5174-5184

Bentham Science Publishers

Access to resources Recommend Favorite